446 related articles for article (PubMed ID: 36364057)
1. Peptide-Drug Conjugates: A New Hope for Cancer Management.
Chavda VP; Solanki HK; Davidson M; Apostolopoulos V; Bojarska J
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364057
[TBL] [Abstract][Full Text] [Related]
2. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.
Lindberg J; Nilvebrant J; Nygren PÅ; Lehmann F
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641586
[TBL] [Abstract][Full Text] [Related]
3. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
4. Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics.
Dean TT; Jelú-Reyes J; Allen AC; Moore TW
J Med Chem; 2024 Feb; 67(3):1641-1661. PubMed ID: 38277480
[TBL] [Abstract][Full Text] [Related]
5. Peptide-drug conjugates: A new paradigm for targeted cancer therapy.
Wang M; Liu J; Xia M; Yin L; Zhang L; Liu X; Cheng Y
Eur J Med Chem; 2024 Feb; 265():116119. PubMed ID: 38194773
[TBL] [Abstract][Full Text] [Related]
6. [Antibody-drug conjugates: design and clinical progress].
Wang YJ; Cao X; Liu XY; Lu XL; Li YY; Jiao BH
Yao Xue Xue Bao; 2016 Aug; 51(8):1209-16. PubMed ID: 29897715
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges.
Payan S; Montana M; Curti C; Greillier L; Vanelle P
Target Oncol; 2020 Aug; 15(4):429-448. PubMed ID: 32725438
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
Ducry L; Stump B
Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
[TBL] [Abstract][Full Text] [Related]
9. Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.
Prabhu S; Boswell CA; Leipold D; Khawli LA; Li D; Lu D; Theil FP; Joshi A; Lum BL
Ther Deliv; 2011 Jun; 2(6):769-91. PubMed ID: 22822508
[TBL] [Abstract][Full Text] [Related]
10. Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management.
Malviya R; Verma S; Sundram S
Curr Cancer Drug Targets; 2022; 22(4):286-311. PubMed ID: 34792003
[TBL] [Abstract][Full Text] [Related]
11. Unlocking the potential of antibody-drug conjugates for cancer therapy.
Drago JZ; Modi S; Chandarlapaty S
Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
[TBL] [Abstract][Full Text] [Related]
12. Recent advances and applications of peptide-agent conjugates for targeting tumor cells.
Alamdari-Palangi V; Jaberi KR; Shahverdi M; Naeimzadeh Y; Tajbakhsh A; Khajeh S; Razban V; Fallahi J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15249-15273. PubMed ID: 37581648
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan.
Dong W; Shi J; Yuan T; Qi B; Yu J; Dai J; He L
Eur J Med Chem; 2019 Apr; 167():583-593. PubMed ID: 30822636
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery and release systems for targeted tumor therapy.
Böhme D; Beck-Sickinger AG
J Pept Sci; 2015 Mar; 21(3):186-200. PubMed ID: 25703117
[TBL] [Abstract][Full Text] [Related]
15. Optimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology.
Subbiah V
Curr Probl Cancer; 2021 Oct; 45(5):100799. PubMed ID: 34706831
[TBL] [Abstract][Full Text] [Related]
16. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).
Cooper BM; Iegre J; O' Donovan DH; Ölwegård Halvarsson M; Spring DR
Chem Soc Rev; 2021 Feb; 50(3):1480-1494. PubMed ID: 33346298
[TBL] [Abstract][Full Text] [Related]
17. Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates.
Raabe M; Heck AJ; Führer S; Schauenburg D; Pieszka M; Wang T; Zegota MM; Nuhn L; Ng DYW; Kuan SL; Weil T
Macromol Biosci; 2022 Feb; 22(2):e2100299. PubMed ID: 34791790
[TBL] [Abstract][Full Text] [Related]
18. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
Rege K; Patel SJ; Megeed Z; Yarmush ML
Cancer Res; 2007 Jul; 67(13):6368-75. PubMed ID: 17616696
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
